

# Phase 1/2 Study of HYP-2090PTSA in Patients With Advanced Solid Tumors Harboring KRAS Mutation

NCT06243354

---

Status	RECRUITING
Phase	Phase 1, Phase 2
Sponsor	Sichuan Huiyu Pharmaceutical Co., Ltd
Enrollment	257 participants

## Key Eligibility Criteria

---

### Inclusion (7)

- A written informed consent should be signed by a subject or his/her legal representative before any study-related procedures are performed;
- Years and older;
- Subjects with histologically or cytologically confirmed locally advanced or metastatic advanced solid tumors;
- Subjects must have at least one measurable lesion as defined by RECIST v1.1;
- Eastern Cooperative Oncology Group(ECOG) performance status 0-1;
- ... and 2 more (see full listing online)

### Exclusion (10)

- Patients who have received major surgical or interventional treatment within 4 weeks prior to the first dose, with the exception of tumor biopsy, puncture, etc. Patients who have received anti-tumor therapy (radiotherapy, immunologic therapy or biological therapy) within 4 weeks, prior to the first dose, or received small molecular targeted therapy, chemotherapy within 2 weeks, or received palliative radiotherapy for bone metastases within 2 weeks, or received nitrosoureas or mitomycin C within 6 weeks;
- Patients who have received live vaccines within 4 weeks prior to the first dose;
- Patients who have previously participated in clinical trials of other drugs within 4 weeks before the first dose;
- Patients with a history of central nervous system disease within 12 months prior to enrollment, such as seizures, cerebral vascular embolism/hemorrhage, paralysis, aphasia, severe brain injury, dementia, Parkinson's disease, cerebellar disease, organic brain syndrome, psychiatric disease, or any autoimmune disease with involvement of the central nervous system;
- Presence of severe pulmonary diseases such as pulmonary embolism, interstitial lung disease at screening;
- ... and 5 more (see full listing online)

## Locations (6 total)

---

Fujian Provincial Cancer Hospital, Fuzhou, Fujian, China  
Hunan Provincial Cancer Hospital, Changsha, Hunan, China  
The first Hospital of China Medical University, Shenyang, Liaoning, China  
... and 3 more locations

---

<https://clinicaltrials.gov/study/NCT06243354>

DISCLAIMER: This document is for informational purposes only and does not constitute medical advice. Always consult your healthcare provider before enrolling in any clinical trial. Information may not be up to date — verify details at [ClinicalTrials.gov](https://clinicaltrials.gov). Generated by [ClinicalTrialsFinder.org](https://clinicaltrialsfinder.org).